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Introduction {#sec005}
============

Tuberculosis (TB) is a serious health threat worldwide, with an estimated 8.6 million incident cases and 1.3 million deaths in 2012 \[[@pone.0129792.ref001]\]. The early detection of this disease is critical to allow for early treatment and prevent further infection. However, a highly sensitive culture-dependent test used for the diagnosis of TB can take approximately 6 to 8 weeks to confirm due to slow mycobacterial growth \[[@pone.0129792.ref002], [@pone.0129792.ref003]\]. Another diagnostic method---sputum smear microscopy---is a rapid, simple, and inexpensive tool for the diagnosis of active TB. Although this method is highly specific in areas with a high TB prevalence, its sensitivity is low and varies in the range of 20--60% \[[@pone.0129792.ref004], [@pone.0129792.ref005]\]. Theoretically, TB nucleic acid amplification tests could detect even the presence of a single mycobacterial cell, but a meta-analysis revealed variable sensitivity (pooled sensitivity 85%, range 36--100%) of this test \[[@pone.0129792.ref006]\].

Immunologic tests, such as the tuberculin skin test (TST) and interferon-γ release assays (IGRAs), can help clinicians diagnose TB and latent *Mycobacterium tuberculosis* infection (LTBI) by demonstrating immunologic response to *M*. *tuberculosis* antigens. While these tests cannot differentiate active disease from latent infection, and cannot differentiate current and resolved infection, they can facilitate diagnostic decisions when used in conjunction with other clinical information \[[@pone.0129792.ref007], [@pone.0129792.ref008]\].

The QuantiFERON-TB Gold In-Tube Test (QFT-GIT, Cellestis/Qiagen, Carnegie, Australia) is one of several commercially available IGRAs \[[@pone.0129792.ref009], [@pone.0129792.ref010]\]. QFT-GIT uses an enzyme-linked immunosorbent assay (ELISA) to quantify the interferon-γ response of fresh whole blood to a cocktail of *M*. *tuberculosis* antigens. The cocktail represents three *M*. *tuberculosis* proteins, early secretory antigenic target-6 (ESAT-6), culture filtrate protein-10 (CFP-10), and TB7.7. These antigens are not present in any bacillus Calmette---Guérin (BCG) vaccine strain and are absent from most nontuberculous mycobacteria (NTM). As a result, QFT-GIT may be more specific in people who have received BCG or infected with certain NTM. In recent meta-analyses, pooled QFT-GIT sensitivity among persons with confirmed TB ranged from 65 to 84% with the lowest sensitivity among those with human immunodeficiency virus (HIV) infection \[[@pone.0129792.ref007], [@pone.0129792.ref008], [@pone.0129792.ref011]\]. As a result of inadequate sensitivity, IGRAs are considered insufficient to rule out active TB \[[@pone.0129792.ref012]--[@pone.0129792.ref022]\]. Identification of the host factors associated with false-negative and indeterminate QFT-GITs may improve their utility as diagnostic aids.

Methods {#sec006}
=======

Study population {#sec007}
----------------

This is a retrospective review of patients without HIV infection who were older than 18 years, diagnosed with culture-confirmed TB at one of the six South Korean hospitals with \>500 beds between May 2007 and February 2014, and who had QFT-GIT completed prior to receiving TB treatment. QFT-GIT is performed according to the discretion of the treating clinician. These patients were identified by positive results on TB culture from sputum, bronchial washes, body fluids, and tissue samples. The clinical, radiographic, and bacteriological status data were retrospectively collected from these patients. The presence of miliary TB and bilateral disease was determined by chest radiography. Heavy drinking is defined as the consumption of ≥ 40 g pure alcohol/day for men and ≥ 20 g pure alcohol/day for women\[[@pone.0129792.ref023]\]. HIV was detected by screening using Architect HIV Ag/Ab Combo Kit (Abbott Laboratories, Abbot Park, IL, USA) to determine the presence of HIV antibody and/or antigen and confirming using an additional HIV western blot test (HIV BLOT 2.2 Western Blot Assay, MP Diagnostics, Asia Pacific Pte Ltd., Singapore). With respect to co-morbid conditions, chronic pulmonary disease was defined as a non-infectious chronic pulmonary disease such as chronic obstructive pulmonary disease and asthma. Chronic kidney disease was defined as a disease causing a progressive loss of renal function. Chronic heart disease was defined as disease requiring the long-term use of cardiac medications, such as coronary artery disease, valvular heart disease, cardiomyopathy, and cardiac arrhythmias. Chronic liver disease was defined as a disease causing progressive destruction and regeneration of the liver parenchyma such as chronic viral hepatitis, alcoholic liver disease, and liver cirrhosis. Anemia was defined according to the World Health Organization guidelines as baseline hemoglobin content \< 13 g/dL in men or \< 12 g/dL in women \[[@pone.0129792.ref024]\]. Lymphocytopenia was defined as a blood lymphocyte count \< 1.0 × 10^9^/L.

QuantiFERON-TB Gold In-Tube Test {#sec008}
================================

QuantiFERON-TB Gold In-Tube Test (Cellestis, Victoria, Australia) were performed according to the manufacturer's instructions. Briefly, three blood collection tubes were used: Nil control tube (negative control without antigens or mitogen), control tube (positive control containing phytohemagglutinin), and TB antigen tube (containing a peptide cocktail simulating the *M*. *tuberculosis*-specific antigens ESAT-6, CFP-10, and TB7.7). The blood tubes were incubated for 20 h at 37°C. The IFN-γ concentrations were then measured by ELISA with an automated microplate processor (Evolis Twin Plus system; Bio-Rad Laboratories, Hercules, CA, USA).

The QFT-GIT results for each patient were interpreted according to the manufacturer's criteria. Briefly, the QFT-GIT result was defined as positive if the IFN-γ level of Nil was ≤ 8.0 IU/mL and that of TB antigen minus Nil was ≥ 0.35 IU/mL and ≥ 25% of Nil value. Negative results was defined if the IFN-γ level of Nil was ≤ 8.0 IU/mL, that of Mitogen minus Nil was ≥ 0.5 IU/mL, and that of TB antigen minus Nil was \< 0.35 IU/mL or \< 25% of Nil value. The results were reported as indeterminate if the IFN-γ level of Nil was ≤ 8.0 IU/mL, that of TB antigen minus Nil was\< 0.35 IU/mL or ≥ 0.35 IU/mL and \< 25% of Nil value, and Mitogen minus Nil was \< 0.5 IU/mL (positive control failure) or if the IFN-γ level of Nil was \> 8.0 IU/mL (negative control failure).

Statistical analyses {#sec009}
--------------------

Values are expressed as medians and in the interquartile range (IQR), or as numbers (percentages) in the text and tables. Continuous comparison were performed using the Mann-Whitney *U* test, and categorical comparisons were performed using the Chi-squared or Fisher's exact tests between variables in patients with positive and negative QFT-GIT results. The risk factors for negative and indeterminate QFT-GIT results were evaluated by univariate comparison of all clinical and laboratory variables in [Table 1](#pone.0129792.t001){ref-type="table"} between those with positive and those with negative QFT-GIT results, and between those with positive and those with indeterminate QFT-GIT results. Variables with p values \< 0.2 were included in subsequent multiple logistic regression tests. In order to detect the existence of collinearity in the variables in multiple logistic regression tests, we measured the variance inflation factor (VIF) and factors with VIF \> 5 were considered as a presence of collinearity. In regression analysis, variables to be maintained in the final model were selected by stepwise and backward regression; a p value \< 0.05 were considered statistically significant. The data were analyzed using SPSS for Windows version 21.0 (SPSS, IBM, Armonk, NY, USA).

10.1371/journal.pone.0129792.t001

###### Baseline characteristics of patients with tuberculosis.

![](pone.0129792.t001){#pone.0129792.t001g}

  Characteristic                                                            N (%), Median (IQR)[^a^](#t001fn002){ref-type="table-fn"}   Total
  ------------------------------------------------------------------------- ----------------------------------------------------------- -------
  Age, years                                                                53.0 (35.0--69.0)                                           1,264
    ≥65                                                                     405 (32.0)                                                  1,264
  Sex, male                                                                 718 (56.8)                                                  1,264
  Body mass index, kg/m^2^                                                  21.2 (19.0--23.1)                                           1,145
    \<18.5                                                                  220 (19.2)                                                  1,145
  Symptoms                                                                                                                              
    Cough                                                                   555 (44.0)                                                  1,260
    Sputum                                                                  415 (32.9)                                                  1,260
    Dyspnea                                                                 194 (15.4)                                                  1,258
    Fever                                                                   257 (20.4)                                                  1,259
    Hemoptysis                                                              89 (7.1)                                                    1,259
    Weight loss                                                             183 (14.5)                                                  1,259
    No symptoms                                                             323 (25.7)                                                  1,258
  Ever smoked                                                               479 (43.7)                                                  1,096
  Heavy drinking                                                            124 (14.3)                                                  865
  Previous TB history                                                       165 (13.1)                                                  1,263
  Smear-positive sputum                                                     422 (37.8)                                                  1,115
  Cavity (or cavities) on chest radiograph                                  185 (14.7)                                                  1,260
  Bilateral disease                                                         286 (22.7)                                                  1,259
  Miliary TB                                                                48 (3.8)                                                    1,260
  Disseminated TB                                                           57 (4.5)                                                    1,259
  Sites of disease                                                                                                                      1,264
    Pulmonary TB                                                            1106 (87.5)                                                 1,264
    Extrapulmonary TB                                                       158 (12.5)                                                  1,264
  ICU admission                                                             30 (2.4)                                                    1,245
  Co-morbid conditions                                                                                                                  
    Chronic pulmonary disease                                               27 (2.1)                                                    1,260
    Chronic kidney disease                                                  39 (3.1)                                                    1,260
    Chronic heart disease                                                   85 (6.7)                                                    1,260
    Diabetes mellitus                                                       203 (16.1)                                                  1,260
    Neurologic disease                                                      42 (3.6)                                                    1,260
    Chronic liver disease                                                   65 (5.2)                                                    1,260
    Rheumatologic disease                                                   17 (1.3)                                                    1,260
    Malignancy                                                              92 (7.3)                                                    1,264
  Immunosuppressive agent use                                               12 (1.0)                                                    1,260
  Laboratory findings                                                                                                                   
    Hemoglobin, g/dL                                                        12.7 (11.2--13.9)                                           1,236
    Anemia (hemoglobin content of \<130 g/L in men or \<120 /dL in women)   563 (45.6)                                                  1,236
    Lymphocyte, cells/mm^3^                                                 1422.1 (939.5--1931.3)                                      1,178
    Lymphocytopenia (\<1.0 × 10^9^/L)                                       294 (25.0)                                                  1,178
    Platelet, × 10^9^/L                                                     255.0 (198.0--318.0)                                        1,261
    Glucose, mmol/L                                                         107.0 (94.0--129.0)                                         1,121
    Total protein, g/L                                                      6.9 (6.2--7.4)                                              1,223
    Albumin, g/L                                                            3.8 (3.2--4.2)                                              1,232
    CRP, mg/L                                                               1.8 (0.3--6.1)                                              1,192

IQR, interquartile range; TB, tuberculosis; ICU, intensive care unit; CRP, C-reactive protein.

^a^The data are presented as medians (IQR) for age, body mass index, and hemoglobin and as n (%) for all other factors.

Ethics statement {#sec010}
----------------

The Institutional Review Board of Chonnam National University Hospital approved this study and has given permission for it to be reviewed and published, including information obtained from patient records (IRB No. CNUH-2014-229). Informed consent was waived because of the retrospective nature of the study, and patient information was anonymized and de-identified prior to analysis.

Results {#sec011}
=======

Of the 9,181 patients suspected to have active TB, the following were excluded: those with negative results in TB culture in clinical specimen (n = 4,965), those not subjected to the QFT-GIT before the start of medication (n = 2,943), and those with confirmed HIV antibodies (n = 9). A total of 1,264 patients whose specimen cultures confirmed active TB infection, and who were tested with QFT-GIT prior to medication were included in this study.

Of the 1,264 culture-confirmed TB patients, 1082 (85.6%) had positive, 182 (14.4%) had negative, and 40 (3.2%) had indeterminate QFT-GIT results. The patients' baseline characteristics are shown in [Table 1](#pone.0129792.t001){ref-type="table"}.

In the univariate analysis for the predictive factors of negative QFT-GIT results, age ≥ 65 years and body mass index (BMI) \< 18.5 kg/m^2^, presence of dyspnea, bilateral disease on chest radiography, and ICU admission when the test was performed were considered significant. Among the laboratory findings, anemia, lymphocytopenia, total protein, albumin,and C-reactive protein were significant. Among the co-morbid conditions, the presence of malignancy was significant. Multivariate analysis showed that age ≥ 65 years, bilateral disease, malignancy, and lymphocytopenia were significant predictive factors for negative QFT-GIT results ([Table 2](#pone.0129792.t002){ref-type="table"}). There were no collinarities among variables in the multiple logistic regression tests (VIFs \< 2.1).

10.1371/journal.pone.0129792.t002

###### Predictors of negative QuantiFERON-TB Gold In-Tube Test results in patients with culture confirmed tuberculosis.

![](pone.0129792.t002){#pone.0129792.t002g}

  Patient characteristic           Positive[^a^](#t002fn002){ref-type="table-fn"}   Negative[^a^](#t002fn002){ref-type="table-fn"}   Univariate analyses   Multivariate logistic regression analyses                       
  -------------------------------- ------------------------------------------------ ------------------------------------------------ --------------------- ------------------------------------------- ------------------- -------
  Age ≥ 65 years                   318/1,082 (29.4)                                 68/142 (47.9)                                    2.21 (1.55--3.15)     \<0.001                                     1.60 (1.05--2.43)   0.029
  Body mass index \< 18.5kg/m^2^   178/983 (18.1)                                   34/128 (26.6)                                    1.64 (1.07--2.50)     0.023                                                           
  Dyspnea                          149/1,076 (13.8)                                 30/142 (21.1)                                    1.67 (1.08--2.58)     0.022                                                           
  Fever                            205/1,077 (19.0)                                 37/142 (26.1)                                    1.50 (1.00--2.25)     0.050                                                           
  Bilateral disease                220/1,078 (88.4)                                 46/141 (32.6)                                    1.89 (1.29--2.77)     0.001                                       1.78 (1.14--2.76)   0.011
  Miliary TB                       35/1,079 (3.2)                                   8/141 (5.7)                                      1.79 (0.82--3.95)     0.149                                                           
  Disseminated TB                  43/1,077 (4.0)                                   9/142 (6.3)                                      1.63 (0.78--3.41)     0.198                                                           
  ICU admission                    19/1,066 (1.8)                                   8/141 (5.7)                                      3.32 (1.42--7.72)     0.005                                                           
  Diabetes mellitus                161/1,078 (14.9)                                 29/142 (20.4)                                    1.46 (0.94--2.27)     0.092                                                           
  Neurologic disease               36/1,078 (3.3)                                   9/142 (6.3)                                      1.96 (0.92--4.16)     0.080                                                           
  Malignancy                       71/1,082 (6.6)                                   17/142 (12.0)                                    1.94 (1.11--3.39)     0.021                                       2.50 (1.33--4.60)   0.004
  Anemia                           453/1,058 (42.8)                                 84/139 (60.4)                                    2.04 (1.42--2.93)     \<0.001                                                         
  Lymphocytopenia                  225/1,004 (22.4)                                 48/134 (35.8)                                    1.93 (1.32--2.83)     0.001                                       1.91 (1.24--2.95)   0.003
  Total protein, g/L               69 (63--74) (n = 1,046)                          6.60 (5.90--7.25) (n = 137)                      0.76 (0.63--0.93)     0.006                                                           
  Albumin, g/L                     39 (33--43) (n = 1,054)                          3.45 (2.80--4.00) (n = 138)                      0.50 (0.39--0.65)     \<0.001                                                         
  CRP, mg/L                        18 (3--61) (n = 1,023)                           3.34 (0.70--8.47) (n = 131)                      1.05 (1.02--1.08)     0.002                                                           

OR, odds ratio; CI, confidence interval; TB, tuberculosis; ICU, intensive care unit; CRP, C-reactive protein

^a^The data are presented as medians (IQR) for total protein, albumin, and CRP and as n (%) for all other factors.

The predictive factors for indeterminate QFT-GIT results were evaluated by grouping the QFT-GIT results into positive and indeterminate sets. Symptoms of dyspnea, bilateral disease, diabetes mellitus (DM), immunosuppressive agent use, and low albumin levels, were the independent predictive factors for indeterminate QFT-GIT results in patients with culture-confirmed TB ([Table 3](#pone.0129792.t003){ref-type="table"}). There were no collinarities among variables in the multiple logistic regression tests (VIFs \< 2.1).

10.1371/journal.pone.0129792.t003

###### Predictors of indeterminate QuantiFERON-TB Gold In-Tube test results in patients with culture confirmed tuberculosis.

![](pone.0129792.t003){#pone.0129792.t003g}

  Characteristic                Positive[^a^](#t003fn002){ref-type="table-fn"}   Indeterminate[^a^](#t003fn002){ref-type="table-fn"}   Univariate analyses   Multivariate logistic regression analyses                        
  ----------------------------- ------------------------------------------------ ----------------------------------------------------- --------------------- ------------------------------------------- -------------------- ---------
  Age ≥ 65 years                318/1,082 (29.4)                                 19/40 (47.5)                                          2.17 (1.15--4.10)     0.016                                                            
  Sex, female                   472/1,082 (43.6)                                 22/40 (55.0)                                          1.58 (0.84--2.98)     0.158                                                            
  Dyspnea                       149/1,076 (13.8)                                 15/40 (37.5)                                          3.73 (1.92--7.25)     \<0.001                                     2.29 (1.08--4.85)    0.031
  Weight loss                   149/1,077 (13.8)                                 11/40 (27.5)                                          2.36 (1.16--4.83)     0.018                                                            
  Fever                         205/1,077 (19.0)                                 15/40 (37.5)                                          2.55 (1.32--4.93)     0.005                                                            
  Bilateral disease             220/1,078 (20.4)                                 20/40 (50.0)                                          3.90 (2.06--7.38)     \<0.001                                     3.38 (1.65--6.94)    0.001
  Miliary TB                    35/1,079 (3.2)                                   5/40 (12.5)                                           4.26 (1.57--11.53)    0.004                                                            
  Disseminated TB               43/1,077 (4.0)                                   5/40 (12.5)                                           3.44 (1.28--9.20)     0.014                                                            
  ICU admission                 19/1,066 (1.8)                                   3/38 (7.9)                                            4.72 (1.34--16.71)    0.016                                                            
  Chronic renal disease         28/1,078 (2.6)                                   6/40 (15.0)                                           6.62 (2.57--17.04)    \< 0.001                                                         
  Diabetes mellitus             161/1,078 (14.9)                                 13/40 (32.5)                                          2.74 (1.39--5.43)     0.004                                       2.58 (1.20--5.54)    0.015
  Chronic liver disease         54/1,078 (5.0)                                   5/40 (12.5)                                           2.71 (1.02--7.19)     0.045                                                            
  Rheumatic disease             13/1,078 (1.2)                                   2/40 (5.0)                                            4.32 (0.94--19.78)    0.060                                                            
  Immunosuppressive agent use   9/1,078 (0.8)                                    2/40 (5.0)                                            6.25 (1.31--29.93)    0.022                                       9.34 (1.33--66.24)   0.025
  Anemia                        453/1,058 (42.8)                                 26/39 (66.7)                                          2.67 (1.36--5.26)     0.004                                                            
  Lymphocytopenia               225/1,004 (22.4)                                 21/40 (52.5)                                          3.83 (2.02--7.24)     \<0.001                                                          
  Total protein, g/L            6.90 (6.30--7.40) (n = 1,046)                    5.75 (5.23--7.10) (n = 40)                            0.42 (0.30--0.58)     \<0.001                                                          
  Albumin, g/L                  3.90 (3.30--4.30) (n = 1,054)                    2.85 (2.50--3.40) (n = 40)                            0.20 (0.12--0.32)     \<0.001                                     0.22 (0.13--0.39)    \<0.001
  CRP, mg/L                     1.80 (0.30--6.10) (n = 1,023)                    5.62 (1.91--14.01) (n = 38)                           1.10 (1.06--1.15)     \<0.001                                                          

OR, odds ratio; CI, confidence interval; TB, tuberculosis; ICU, intensive care unit; CRP, C-reactive protein.

^a^The data are presented as medians (IQR) for total protein, albumin, and CRP and as n (%) for all other factors.

Discussion {#sec012}
==========

To our knowledge, this multicenter study that included 1,264 culture-confirmed TB patients is the largest to date evaluating host risk factors resulting in false negative QFT-GIT. We found that some host factors that can lead to low cell-mediated immune responses, such as old age, extensive disease, malignancy, and lymphocytopenia were independent risk factors.

Old age remains a known risk factor for false-negative IGRA results and the current study supports these findings \[[@pone.0129792.ref012]--[@pone.0129792.ref014], [@pone.0129792.ref017], [@pone.0129792.ref018], [@pone.0129792.ref021]\]. The IFN-γ response in the QFT-GIT was decreased in elderly patients (≥80 years) with culture-confirmed TB, and the median age of patients with negative results was also higher \[[@pone.0129792.ref017], [@pone.0129792.ref018]\]. Age was also an independent risk factor for negative results being observed in smear-positive pulmonary TB as well as for indeterminate or negative results in culture-confirmed TB \[[@pone.0129792.ref013], [@pone.0129792.ref014]\]. We observed that advanced age (≥65 years of age) is an independent predictive factor for negative QFT-GIT results in patients with active TB, which was consistent with the findings of previous studies. However, age was not a significant predictive factor for indeterminate results in multivariate analysis. Some studies about the predictors for indeterminate QFT-GIT results also did not show older age as an independent factor. Therefore further studies are needed to evaluate this issue.

The relationship between disease severity and IFN-γ production was also analyzed; decreased IFN-γ production in patients with severe TB was reported in both HIV-negative and HIV-positive patients \[[@pone.0129792.ref025]\]. More radiographically severe disease was also significantly associated with negative QFT-GIT results, which suggests that the low QFT-GIT sensitivity in patients with TB may be related to the immunological inability of the host to contain mycobacterial replication \[[@pone.0129792.ref020]\]. These results are consistent with those of our study, which showed bilateral disease as an independent predictive factor for negative QFT-GIT results, despite miliary TB being significant only in univariate analysis. Dyspnea was an independent predictor for the evaluation of indeterminate QFT-GIT results. This might also be explained by severity of disease since extensive disease could cause frequent dyspnea in patients with active TB.

Immunosuppression can be a risk factor for negative IGRA results in patients with TB infections, and several studies have confirmed these findings in patients with active TB \[[@pone.0129792.ref015], [@pone.0129792.ref016], [@pone.0129792.ref021], [@pone.0129792.ref026], [@pone.0129792.ref027]\]. However, inconsistencies were observed according to different definitions of immunosuppression, and smaller patient number may have limited these findings. Malignancy was a risk factor for decreased QFT-GIT sensitivity, a finding that is consistent with previous studies \[[@pone.0129792.ref015], [@pone.0129792.ref016], [@pone.0129792.ref026]\].

Our study found an association between DM and indeterminate QFT-GIT results in patients with culture-confirmed TB. The reported sensitivity of QFT-GIT in diabetic TB patients is variable. Although some studies reported high sensitivity of QFT-GIT in diabetic TB patients \[[@pone.0129792.ref015], [@pone.0129792.ref028], [@pone.0129792.ref029]\], a recent study demonstrated a decrease in sensitivity of QFT-GIT in diagnostic TB patients \[[@pone.0129792.ref030]\]. Some of the proposed causes of the high incidence of indeterminate results include delayed *M*. *tuberculosis*-specific IFN-γ production in the lymph nodes of diabetic mice, as measured by enzyme-linked immunospot (ELISPOT), and decreased levels of *M*. *tuberculosis*-specific antigen-stimulated IFN-γ production in the whole blood of DM patients with latent TB infection \[[@pone.0129792.ref031], [@pone.0129792.ref032]\].

Among laboratory characteristics, lymphocytopenia was an independent risk factor in this study. QFT-GIT depends on the elaboration of IFN-γ by T lymphocytes previously sensitized with *M*. *tuberculosis*-specific antigens after stimulation \[[@pone.0129792.ref010]\]. Therefore, lymphocytopenia can decrease the production of IFN-γ and can cause false negative QFT-GIT results \[[@pone.0129792.ref018], [@pone.0129792.ref020], [@pone.0129792.ref026]\]. ypoalbuminemia can reflect poor nutritional status in patients that may result in suppression of the systemic immune response. In our study, low serum albumin level was an independent predictive factor for indeterminate results in patients with active TB.

Our study has limitations. First, the data analysis was conducted retrospectively and quantitative QFT-GIT results were not collected. Second, the number of patients who received immunosuppressive drugs was rather small. Therefore the power of our study to detect the impact of these patients in QFT-GIT may be weak. Finally, further studies are necessary to determine whether all of the factors identified in our study also affect the results of ELISPOT-based assays.

In conclusion, here we identified some host factors such as advanced age, extensive pulmonary TB, malignancy, and lymphocytopenia that can potentially lead to negative QFT-GIT results in patients with culture-confirmed TB. Consequently, QFT-GIT results need to be interpreted carefully in patients with these host risk factors.
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